News

  • Reset
Mayne Pharma SA Employees email size_(c)kaycannliveshots-17

Mayne Pharma recipient of $4.8m Federal Government Grant

9 May 2022

Mayne Pharma Group Limited is pleased to announce that its application for a Federal Government Modern Manufacturing Initiative (MMI) Grant has been successful.

Learn more

Ms Ann Custin

Non Executive Director appointment

22 Mar 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Ann Custin has accepted an invitation to join the Board of Mayne Pharma, effective 23 March 2022.

Learn more

Financial,Data,Graph,Chart,,Vector,Illustration.,Abstract,Background,With,Graph

Mayne Pharma 2022 Half Year Results Media Release

25 Feb 2022

Mayne Pharma’s CEO, Mr Scott Richards said, “At a group level, our underlying results this half have incorporated our significant investment in commercial infrastructure to support the launch of NEXTSTELLIS.

Learn more

Female looking into mirror

Mayne Pharma expands US dermatology portfolio

10 Feb 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has launched an authorised generic (AG) of one of the largest dermatology products in the United States.

Learn more

Dr Kathryn MacFarlane

Non Executive Director appointment and retirement

17 Jan 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that Kathryn MacFarlane, PharmD, has accepted an invitation to join the Board of Mayne Pharma, effective 1 February 2022.

Learn more

female doctor with female patient

Mayne Pharma adds a generic PROTOPIC® to US portfolio

12 Jan 2022

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has begun distribution of tacrolimus ointment, 0.1% in the United States

Learn more

Contraceptive Packet

TGA approval of novel oral contraceptive NEXTSTELLIS®

29 Nov 2021

Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of estetrol and 3 mg drospirenone tablets).

Learn more

Mayne Pharma 2021 AGM Chairman's Address

2021 AGM Chairman’s Address

23 Nov 2021

Welcome everyone, I'm Frank Condella, the Chair of Mayne Pharma. It is a pleasure to welcome you to Mayne Pharma’s 2021 Annual General Meeting. As we have a quorum present, I am delighted to open the meeting

Learn more

Mayne Pharma 2021 AGM CEOs Speech

2021 AGM CEO’s Speech

23 Nov 2021

Today I will provide you with an update on the launch of NEXTSTELLIS our novel contraceptive which received FDA approval earlier this year together with some comments around our evolving specialty products business model and our outlook.

Learn more